ERBB2 and inflammatory breast carcinoma: The treatment of HER2-positive IBC has been revolutionized by the FDA approval of targeted therapies in the appropriate clinical settings, including the monoclonal antibodies trastuzumab and pertuzumab, the antibody-drug conjugates (ADC) trastuzumab emtansine (T-DM1) and fam-trastuzumab deruxtecan-nxki (T-DXd), and the tyrosine kinase inhibitors lapatinib and neratinib.